A best evidence topic was constructed according to a structured protocol. The following question was addressed: of the following two procedures, heart-lung transplantation or bilateral-lung transplantation (BLTx), which offers the best outcome for patients with pulmonary hypertension (PH) listed for thoracic transplantation? Of the 77 papers found using a report search for PH and thoracic transplantation, 9 represented the best evidence to answer this clinical question. Overall, 1189 (67%) lung transplantations and 578 (33%) heart-lung transplantations have been reported worldwide for idiopathic PH. For patients with Eisenmenger's syndrome, HLTx represents up to 70% of the transplantation procedures they undergo. On the whole, neither procedure demonstrated an overall survival benefit, when compared with the other. However, PH patients represent a heterogeneous population according to (i) the primary mechanism of PH and (ii) the consequences of PH on right or/and left heart function. With regard to the latter consideration, the current evidence shows that HLTx offers excellent functional and survival outcomes for patients with congenital heart disease and Eisenmenger's syndrome, severe right or/ and left heart dysfunction, and who are chronically inotropic dependent. As far as heart dysfunction is concerned, the published evidence approximated cut-off values at 10-25% for the right ventricle ejection fraction (RVEF) and at 32-55% for the left ventricle ejection fraction (LVEF). In the case of lower values for RVEF and LVEF, HLTx should be performed. In all other patients with PH, the evidence demonstrated that BLTx offers a comparable outcome with the advantage of better organ sharing for other recipients. In order to reduce the waiting time on transplantation lists, cardiac repair and BLTx can be offered in experienced centres to patients with simple cardiac anomalies such as atrial septal defect, patent ductus arteriosus or perimembranous ventricular septal defect.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. The protocol is fully described in the ICVTS [1] .
THREE-PART QUESTION
Of the following two procedures, [heart-lung transplantation] or [bilateral-lung transplantation], which offers the best survival for adult patients listed with [ pulmonary hypertension] and how should the procedure be selected?
CLINICAL SCENARIO
A 43-year old male was referred to a transplantation centre with a New York Heart Association (NYHA) functional Class IV and rapidly progressive primitive pulmonary hypertension (PH). The patient was put under intravenous epoprostenol therapy associated with sildenafil. Despite maximal medical therapy, clinical improvement was limited to NYHA functional Class III. On the 6-min walk test, the patient performed <350 m and cardiac index measured <2 l/min/m 2 . According to official guidelines, this patient met the criteria for thoracic transplantation [2] . An echocardiography measured the left ventricle ejection fraction (LVEF) at 40%. Concern regarding the possible recovery advantages of bilateral-lung transplantation (BLTx), or the need for heart-lung transplantation (HLTx), was raised. We therefore decided to look up the evidence in the literature.
SEARCH STRATEGY
Using the Ovid interface, Medline 1990-July 2012, our literature search was limited to English-language articles with the following key terms: ("pulmonary hypertension.mp) AND ("heart-lung transplantation.mp") AND ("lung transplantation.mp"). Finally, a manual search was used to follow-up on the references from the retrieved studies.
SEARCH OUTCOME
A total of 77 abstracts were found, from which 9 articles were selected for providing the best evidence on the topic. These articles are documented in Table 1 . • Severe right heart failure, enlargement or dysfunction 
RESULTS

Bando et al. [3] conducted a prospective study of patients who underwent single-lung transplantation (SLTx), BLTx or HLTx. The indication was PH caused either by primary PH (PPH) or by Eisenmenger's syndrome (ES)
. HLTx was performed when LVEF measured <35%, or when significant coronary artery disease, or ES, caused by surgically irreparable complex congenital heart disease (CHD), was diagnosed. Survival was better in BLTx and HLTx than in SLTx recipients (P = ns). Allograft actuarial survival was better in BLTx and HLTx (P < 0.05) patients, when compared with SLTx patients. BLTx and HLTx patients demonstrated an improvement in NYHA functional class (P < 0.05), cardiac index increase (P < 0.05) and in reducing mean pulmonary artery pressure (P < 0.05). Conte et al. [4] compared the survival of patients with PPH or secondary PH (SPH), according to the procedure they had undergone (BLTx or SLTx). In the PPH group, BLTx patients had a better overall survival (P < 0.05). In the SPH group, no significant difference in survival, related to the procedure, was shown. There were no differences in the incidence of rejections, infections or other complications between patients who had undergone SLTx or BLTx. The authors reported a better survival for BLTx patients with a mean pulmonary artery pressure superior to 40 mmHg, prior to transplantation (P = 0.19).
Stoica et al. [5] retrospectively reviewed all ES patients undergoing HLTx (n = 51). The outcomes of these patients were compared with those of all the other patients (n = 212) undergoing the same procedure in the same institution for another indication. No significant difference in overall survival between the two groups (P = 0.54) was shown. A subgroup analysis could not demonstrate any difference between simple and complex ES patients who had undergone HLTx.
Pielsticker et al. [6] conducted a survey of worldwide practice patterns for treating PH with a transplantation procedure. Thirty-five PH centres answered with the complete data. For 83% of the centres, the preferred procedure was BLTx. Criteria for choosing HLTx was most frequently left ventricle (LV) function (76%), RV function criteria (45%) and the degree of tricuspid valve regurgitation (27%). The measured LVEF and right ventricle ejection fraction (RVEF) cut-off ranged from 32 to 55% and 15 to 25%, respectively.
Wadell et al. [7] analysed the United Network for Organ Sharing/International Society for Heart-Lung Transplantation (ISHLT) joint transplant registry to assess the relevance of HLTx for ES patients, in comparison with lung transplantation (LTx) with cardiac repair. The authors compared the survival of 605 end-stage ES patients according to the transplantation procedure. HLTx appeared to be the safest procedure, with a significantly higher survival rate in comparison with LTx (P = 0.002). Survival of ventricular septal defect (VSD) patients was significantly better for those who underwent HLTx than those who underwent LTx (P = 0.0001).
Toyoda et al. [8] carried out a retrospective review of all patients transplanted (HLTx or LTx) for idiopathic pulmonary arterial hypertension (IPAH). The authors compared long-term outcome by the era of transplantation. Survival improved for the most recently transplanted patients (P = 0.004). There was no survival difference between the different types of procedures (HLTx, BLTx or SLTx).
Fadel et al. [9] reviewed all patients who underwent HLTx or BLTx for PH. They reported 152 HLTx procedures in comparison with 67 BLTx procedures. HLTx was selected in the case of severe right-heart enlargement and dysfunction, congenital systemic-to-pulmonary shunt (CSPS, i.e. ES), lowered cardiac index (<2.2 l/min/m 2 ), severe preoperative renal failure or if patients were chronically dependent on inotropic support. Otherwise, BLTx was performed. No difference in overall survival was found between the two procedures (P = 0.46) performed. There also was no difference in the mean waiting time for a suitable graft (HLTx 8.7 ± 11.8 vs BLTx 6.7 ± 7.5 months; P = 0.2).
Christie et al. [10] reported on the data collected from the ISHLT registry. Half-life and conditional half-life survivals calculated for BLTx and HLTx showed similar results (no comparative test was performed). The same observation can be made about HLTx and LTx performed for IPAH. Both procedures appear to offer the same level of safety for PH patients. De Perrot et al. [11] reported their experiences with HLTx and BLTx for all types of PH patients. HLTx was selected in the case of severe LV dysfunction (LVEF <40% and/or the presence of technical limitations for conducting BLTx). The procedure outcomes did not indicate any difference in overall survival between HLTx and BLTx for PH patients, or any difference in survival according to the type of PH indication. CHD patients mainly underwent HLTx, but had to wait longer for a suitable graft (378 ± 306 days; P < 0.0001). However, mortality on the waiting list remained lowest (9%; P = 0.01).
CLINICAL BOTTOM LINE
On the whole, none of the published research confirms an overall survival benefit for HLTx, in comparison with BLTx. BLTx and HLTx are the safest procedures for PH patients. BLTx and HLTx are not alternative procedures, but rather, each is suited for a different type of patient. Indeed, PH patients constitute a heterogeneous group of patients not only due to the mechanisms involved in the development of PH, but also because of the various consequences PH have on right and left ventricle function. In this context, HLTx can offer excellent early and long-term outcomes to patients with CHD and ES, severe right heart dysfunction and/or severe left heart dysfunction, and to those who are chronically dependent on inotropic support. In all other patients, BLTx can provide comparable outcomes with the advantage of better organ sharing for other recipients. Regarding the perioperative risks and rejection rates, the results are quite different from one publication to another. Some authors reported a lower primary graft dysfunction rate and better survival, without bronchiolitis obliterans, when HLTx was performed. As far as waiting time is concerned, PH patients with simple cardiac anomalies such as atrial septal defect, patent ductus arteriosus or perimembranous VSD can be treated with a combination of BLTx and cardiac repair. Cut-off values can be approximated at 10-25% for the RVEF and 32-55% for the LVEF. For any lower values, HLTx should be performed.
